We are live on ! Find out more
SLXP

SALIX PHARMACEUTICALS LTD DEL
SLXP

Delisted

SLXP was delisted on the 31st of March, 2015.

304 hedge funds and large institutions have $6.82B invested in SALIX PHARMACEUTICALS LTD DEL in 2014 Q1 according to their latest regulatory filings, with 78 funds opening new positions, 110 increasing their positions, 98 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

359% more first-time investments, than exits

New positions opened: 78 | Existing positions closed: 17

173% more call options, than puts

Call options by funds: $81.1M | Put options by funds: $29.7M

67% more funds holding in top 10

Funds holding in top 10: 610 (+4)

24% more funds holding

Funds holding: 246304 (+58)

12% more repeat investments, than reductions

Existing positions increased: 110 | Existing positions reduced: 98

8% more capital invested

Capital invested by funds: $6.3B → $6.82B (+$520M)

Holders
304
Holders Change
+58
Holders Change %
+23.58%
% of All Funds
8.78%
Holding in Top 10
10
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+66.67%
% of All Funds
0.29%
New
78
Increased
110
Reduced
98
Closed
17
Calls
$81.1M
Puts
$29.7M
Net Calls
+$51.5M
Net Calls Change
+$4.64M
Name Holding Trade Value Shares
Change
Change in
Stake
DWA
176
Dorsey Wright & Associates
California
$1.64M -$90.4K -883 -6%
PG
177
PEAK6 Group
Illinois
$1.63M +$1.05M +10,212 +186%
DC
178
Deere & Company
Illinois
$1.59M -$215K -2,104 -12%
PA
179
Profund Advisors
Maryland
$1.59M +$133K +1,299 +9%
VanEck Associates
180
VanEck Associates
New York
$1.59M -$736K -7,184 -32%
IRF
181
IBM Retirement Fund
New York
$1.59M -$925K -9,030 -37%
FWCM
182
First Western Capital Management
California
$1.57M +$12.8K +125 +0.8%
CIC
183
Chase Investment Counsel
Virginia
$1.55M -$10.2K -100 -0.7%
Connor, Clark & Lunn Investment Management (CC&L)
184
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$1.48M +$1.32M +12,900 New
Stifel Financial
185
Stifel Financial
Missouri
$1.46M +$1.44M +14,098 New
WSCM
186
Wellington Shields Capital Management
New York
$1.42M +$76.3K +745 +6%
Los Angeles Capital Management
187
Los Angeles Capital Management
California
$1.37M -$805K -7,860 -37%
GH
188
GAM Holding
Switzerland
$1.29M +$102K +1,000 +9%
Nordea Investment Management
189
Nordea Investment Management
Sweden
$1.24M
PAM
190
Princeton Alpha Management
New Jersey
$1.19M +$1.17M +11,449 New
VKH
191
Virtu KCG Holdings
New York
$1.16M +$1.14M +11,181 New
SB
192
Suntrust Banks
Georgia
$1.15M -$17K -166 -1%
URS
193
Utah Retirement Systems
Utah
$1.14M +$10.2K +100 +0.9%
JG
194
Jefferies Group
New York
$1.13M +$1.12M +10,912 New
MC
195
Menta Capital
California
$1.13M +$1.12M +10,900 New
Jane Street
196
Jane Street
New York
$1.11M +$1.1M +10,710 New
AL
197
Airain Ltd
Guernsey
$1.1M +$1.09M +10,613 New
RI
198
Redwood Investments
Massachusetts
$1.09M -$102 -1 -0%
CMANY
199
Capital Management Associates (New York)
New York
$1.04M
CCM
200
Catapult Capital Management
New York
$1.04M +$1.02M +10,000 New

SLXP Hedge Fund Activity: Q1 2014 in Review

304 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in SALIX PHARMACEUTICALS LTD DEL (SLXP) for Q1 2014, worth a combined $6.82B — up 8.3% from $6.3B a quarter earlier.

Buyers outnumbered sellers: 78 funds opened new SLXP positions and 17 closed out — a net gain of 61 holders — while 110 added to existing stakes and 98 trimmed.

The largest buyer was Viking Global Investors, opening a new position worth an estimated $159M. The largest seller was TIAA CREF Investment Management, cutting an estimated $145M.

  • 304 institutional investors held SALIX PHARMACEUTICALS LTD DEL (SLXP) as of Q1 2014, up from 246 in Q4 2013.
  • Funds reported $6.82B of SALIX PHARMACEUTICALS LTD DEL stock for Q1 2014, up 8.3% quarter-over-quarter.
  • 78 funds opened new SALIX PHARMACEUTICALS LTD DEL positions in Q1 2014 and 17 closed out, a net change of +61 holders.
  • The largest SALIX PHARMACEUTICALS LTD DEL buyer in Q1 2014 was Viking Global Investors, an estimated $159M added.
  • The largest SALIX PHARMACEUTICALS LTD DEL seller in Q1 2014 was TIAA CREF Investment Management, an estimated $145M sold.

Based on aggregated 13F filings for Q1 2014.